United European Gastroenterology Week (UEGW) 2017
BUHLMANN Laboratories AG
Booth: #64 Hall 8.1
Oct 28 – Nov 1, 2017
LOCATION
Fira de Barcelona Gran Via
Barcelona, Spain
Take the chance to get an update on our Calprotectin and Therapeutic Drug Monitoring product portfolio:
Quantum Blue® platform offering rapid and quantitative results for fecal calprotectin, serum calprotectin, CRP and serum infliximab trough levels. Additional trough level assays coming soon!
IBDoc® calprotectin home test for remote monitoring of IBD patients in remission
BÜHLMANN fCAL® ELISA, the gold standard assay for fecal Calprotectin
BÜHLMANN fCAL® turbo, the new high troughput, random access fecal Calprotectin assay. Available for virtually all Clinical Chemistry Analyzers allowing time to result of 10 minutes.
CALEX® Cap, the new standard in stool extraction
Schuster T. et al.: P1014 – Performance of the BÜHLMANN Quantum Blue® Adalimumab rapid test dedicated for therapeutic drug monitoring of serum adalimumab trough levels
Conclusions: “The BÜHLMANN Quantum Blue® Adalimumab lateral flow test enables the quantitative determination of adalimumab trough level in serum with time to result of only 15 minutes. The developed test allows to measure adalimumab over a wide range, well beyond the therapeutic window. Hence, it represents a valuable tool for the clinician to assess the adalimumab trough level.”
Magro F. et al.: P1022 Clinical perspective on drug monitoring with an infliximab rapid quantification assay
Conclusion: “Our results show that the rapid IFX assessment system is a reliable alternative to the time-consuming ELISAs in patients in the maintenance phase of IFX operating a threshold of 3 ug/ml.”
El-Safi G. et al. P1675: Cost effectiveness of IBDoc faecal calprotectin as a surrogate marker of mucosal healing post induction of biological agents in inflammatory bowel disease.
Conclusion: “This study demonstrates a significant cost-effectiveness of using IBDoc faecal calprotectin post induction of anti-TNF therapy, as well as reducing the waiting time for both clinic visits and colonoscopy.”
Walsh A. et al, P1641: TrueColours ulcerative colitis (TCUC): Will patients with UC complete digital questionnaires in Real-Time?
Conclusion: “Patients with UC will collect digital data in real-time, with good adherence to symptom, QoL, outcome questionnaires and FCal home testing. Usability was classified as ‘superior’ but further improvements are possible. Larger studies are required to determine cost-effectiveness.”
Puolanne M. et al: P0371 – Self-monitoring of the colonic inflammatory bowel disease by a rapid home based feacal calprotectin test and a symptom questionnaire.
Conclusion: “The self-monitoring of IBD activity with a rapid FC home test provides an option for individualized treatment for increasing amount of IBD patients…“
Impressions from BÜHLMANN at UEGW 2016 and two TDM live poster presentations
By loading the video, you agree to YouTube's privacy policy.
Learn more
Social Links